Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

Liver cancer experts attribute the rise in HCC, a highly aggressive cancer sometimes called hepatoma, to an increase decades ago in chronic infection with hepititis C & B and also chronic alcohol consumption. Worldwide liver cancer affects 700,000 people with 18,000 Americans diagnosed in 2006 and over 19,000 estimated to be diagnosed in 2007. The increase of this disease in the United States has doubled in one decade and over 16,000 people are estimated to die from the disease this year.

The rise in the United States is expected to increase. There are now 1.4 million people in the United States infected with HBV and 4 million are infected with HCV. Growing evidence suggests two other diseases now increasingly common in the United States to have significant risk factors for primary liver cancer. Diabetes and obesity.

HCC typically does not have any symptoms until its later stages which makes it difficult to diagnose. Traditional chemo does not treat the disease with much success and liver transplants or resection surgeries are needed. One reason why donors are very important in fighting this disease. When signs and symptoms do arise they might include weight loss, fatigue, pain in the upper right abdomen that may extend to the back and shoulder, feeling full after small meals, accumulation of fluid in the abdomen, nausea, loss of appetite, and jaundice.

First, it seemed eating lycopene-rich tomatoes offered protection against prostate cancer. Now it seems this is not so true. In fact, researchers have found an association between an increased risk of aggressive prostate cancer and beta carotene, an antioxidant related to lycopene.

Lycopene seemed for a short time to be a quick and easy fix for men trying to lower their prostate cancer risk. Yet studies are failing to show any significant differences in blood lycopene levels between men who develop the disease and those who do not.

The largest study to yield these results investigated the role of blood levels of lycopene and other antioxidants in the prevention of prostate cancer. It was an unexpected turn of events that led researchers to the link between the most aggressive cancers and antioxidants found in many vegetables. While the observation may be due to chance, beta carotene is known to increase risk of lung cancer and heart disease in smokers and may be worth a bit more study.

On Tuesday, researchers announced that a three-drug cocktail may help women with HER2-positive breast cancer better than any other drug used on its own. About one quarter of women with breast cancer make up this HER2 category.

Tests on mice revealed using the three drugs along with breast cancer drug tamoxifen helped wipe out tumors altogether. And the tumors did not come back. This is the first time mice were cured of a very aggressive human breast tumor. Incidentally, when a single drug was used, tumors returned within several weeks.

The three wonder drugs used in this study -- all are monoclonal antibodies that precisely target certain aspects of tumors -- are the experimental drug pertuzumab; trastuzumab, also known as Herceptin; and gefitinib, or Iressa.

Published in the Journal of the National Cancer Institute, this study supports the notion that HER2-positive tumors eventually become resistant to one drug and attacking them on several fronts seems to work better.

The Boston Marathon takes place today. And one runner -- known to friends and family as Running Bear -- will run to raise money for brain tumor research. She's already collected more than $3,500.

Harvard student Sarah MacCarthy, 25, will run for her Uncle Tim, who is battling glioblastoma (GBM), the most aggressive form of the primary brain tumors known collectively as gliomas.

If Uncle Tim can fight for his life, MacCarthy can use her privilege of good health to make a difference -- even if it means stepping up her casual running to marathon standards.

The Brain Tumor Society will benefit from MacCarthy's determination. Dedicated to improving quality of life for patients, survivors, and families affected by this disease, BTS is committed to being a national leader in the quest for a cure.

It seems MacCarthy is pretty committed herself. To contribute to her efforts and check on her progress, click here.

ImClone Systems Inc.'s drug Erbitux has failed to help pancreatic cancer patients live longer. It's also failed to grow ImClone's market -- not surprising since it's the company's only drug.

Imclone, partnering with Bristol-Myers Squibb Co., wanted to see Erbitux -- already cleared for use with colon, head, and neck cancers -- extend the lives of patients with cancer marked by a spread to the pancreas.

No one is giving up just yet, and Imclone plans additional tests on Erbitux's use in pancreatic cancer. A study using a combination of Erbitux and Avastin and chemotherapy is up next.

"There are reasons to think Erbitux works in pancreatic cancer, but the current results are not as dramatic as we hoped," said Alex Denner, lead for an executive committee that manages ImClone. "We remain committed to evaluating Erbitux in pancreatic cancer."

If approved, Erbitux will compete with Tarceva, sold by Roche Holding AG, Genentech Inc., and OSI Pharmaceuticals Inc. as a treatment for pancreatic and lung cancers.

About 37,170 new cases of pancreatic cancer are expected to occur in 2007 in the United States. And 33,370 people will die from the disease, according to the American Cancer Society. Pancreatic cancer is one of the most aggressive cancers, and there is no screening option that works at catching the disease in its early stages.

Only about 5 percent of patients with pancreatic cancer are still alive five years after being diagnosed.

A new study shows men are three times more likely to develop certain types of skin cancer than women. But it doesn't have as much to do with sun exposure as we might think.

According to researchers at Ohio State University, gender differences put men at greater risk for non-melanoma skin cancers than their female counterparts.

Researchers tested the effects of UVB rays on mice and found male mice developed tumors earlier. The tumors were also larger and more aggressive than those found in female mice.

The study, published in the April 1 issue of Cancer Research, indicates it could be the higher levels of antioxidants females have in their skin that allow them to fight off tumors better.

This comment just arrived in response to yesterday's post Headed for melanoma, and it's just too raw and powerful to leave buried in the comment section of the site.

So here it is, word for word -- a chilling and empowering message from a 37-year-old mom of two living with a disease that is downright deadly.

I have melanoma. I was diagnosed last August and have had 6 surgeries in 6 months.

I have lost 4 members in my melanoma support group. I go to Jaime's funeral tomorrow afternoon. She was 29 years old. Heather was 37 when she died on March 2, 2007. The midwife noticed a suspicious mole on her leg during the birth of her 4th child. She died 23 months later. Jan was a mother of 5 ages 9 to 19, she passed away on February 8, 2007. Ceri was only 20 years old when melanoma claimed her life on January 14, 2007.

I always thought skin cancer had to be HUGE, ugly, and hard to ignore. I didn't know it could be small, have no symptoms, and KILL you.

Melanoma incidence is increasing faster than any other cancer. According to statistics found on the American Cancer Society's website (www.cancer.org), the prognosis for someone diagnosed with melanoma is worse, stage for stage, than someone with breast cancer.

Getting more than 3 blistering sunburns during childhood doubles your risk. Sunbed use increases ones risk. Having fair skin and light eyes also puts you at a higher than average risk, but having dark skin does not make you immune. Bob Marley died from Melanoma in 1981.

Everyone at higher risk should get screened by a dermatologist every year. And all of us should be checking our own skin each month.

Melanoma is a virulent and aggressive cancer. It begins in the melanocytes, or the pigment in the skin. It presents itself as a change in an existing mole or skin pigment, or in the formation of a new one. It is easily treated in its most early stages. Once it spreads, though, it is often fatal.

Unfortunately, there is no cure for melanoma. Melanoma is one of the cancers that won't respond to conventional chemotherapy. There have been no significant advances in the medical treatment or survival rate in the last 30 years.

More awareness is needed. Most think "it's only skin cancer" and consider it nothing serious. But I can tell you with absolute certainty, they are DEAD wrong.

Some scientists believe that surgery to remove a breast tumor may actually help the cancer spread and have recently reported that this same belief may be the exact reason black women are more likely to die of breast cancer.

There is apparently a widespread belief in parts of Africa and the United States that removing a tumor hastens death.

"I must say that I am sure there is more to this than just a myth," said Michael Retsky of Children's Hospital and Harvard Medical School in Boston, who shares his opinions in the International Journal of Surgery.

Retsky still urges any woman with breast cancer to have her tumor removed. And he says chemotherapy is such standard practice for any cancer threatening to spread. It's a safety net of sorts to catch the cells that get away. So if surgery causes cancer to spread, then in theory, chemotherapy should stop the spread.

Retsky, who is not suggesting any change in clinical practice, thinks the subject needs far more research. American Cancer Society experts, who tend to question this theory, agree.

"Whether or not the theory is correct, I have difficulty with the logic that they employed to get there," said oncologist Dr. Len Lichtenfeld of the American Cancer Society who says women should never delay treatment for breast cancer.

Retsky believes that perhaps surgery, by wounding the body, causes it to produce growth factors that fuel the growth of other, tiny tumors. Or maybe a primary tumor secretes some sort of factor that holds the other tumors in check. When the main tumor is removed, the smaller tumors grow.

But it could be that surgery does not cause a spread at all – and that any belief of this nature has no connection with breast cancer tendencies in black women. It may be that black women just have a genetic predisposition for more aggressive forms of the disease.

If the experimental breast cancer drug Tykerb continues to prove successful in study participants, it could be headed for FDA approval.

Tykerb, now in international study, showed in early studies to be even more effective and to have fewer side effects than similar breast cancer drug Herceptin. Both drugs are part of a cluster of targeted therapies that attack cancer cells while sparing healthy cells. Designed for use on women whose breast cancer is HER2 positive -- meaning it contains too much of an aggressive protein -- Tykerb may be a wonder drug, with the capability of effectively keeping breast cancer at bay.

Dr. Paul Goss of MA General Hospital says, "We're seeing Tykerb, which is a pill, which is easier to take, has a broader attack and gets inside cells. It's like an electrical circuit that's turned on, and Tykerb can pull the lever, the circuit breaker, and switch it off."

Farrah Fawcett turned 60 on Friday. And she's been celebrating this milestone along with a very important message she just received -- she is cancer-free.

Fawcett, former star of the hit 1970s TV drama Charlie's Angels, was diagnosed with anal cancer four months ago and has been enduring an aggressive treatment protocol to treat the disease -- a treatment that appears to have worked.

Her physician, Dr. Gary Gitnick at the University of California, Los Angeles, medical school reports Fawcett "has had a full and complete response to treatment." Recent tests show her cancer is gone -- and Gitnick calls her prognosis excellent.

Fawcett calls the whole experience a hopeful one.

"In the face of excruciating pain and uncertainty, I never lost hope," she said. "I hope that my news might offer some level of inspiration to others who unfortunately must continue to fight the disease."

It's an unsettling journey -- the pursuit of the five-year cancer survival mark. Some say each year of cancer survival makes the future more of a sure thing. And so surviving five years -- the traditional landmark of real remission -- is a big accomplishment. But then there's the perspective of numbers that for me say I have a 93 percent chance of surviving breast cancer for five years. After that, though, there's no telling what will happen. So I am eagerly awaiting the moment when I cross the five-year finish line as I anxiously realize this very same moment may also signal a more dismal outlook.

The paradox hit me straight in the face yesterday as I was waiting for my radiation oncologist to give me another six-month all clear announcement. I was reading the January/February 2007 issue of Coping magazine while I waited. And as I flipped through the pages, I landed right at these words:

Studies show that half of all breast cancer recurrences occur after completion of five years of standard tamoxifen therapy. Additionally, a third of women with estrogen receptor-positive early breast cancer experience a recurrence, and more of half of these recurrences occur more than five years after surgery.

Now this doesn't apply directly to me. My breast cancer was estrogen receptor-negative which makes me a non-candidate for tamoxifen. And this is what scares me. My tumor was aggressive and while my treatment was also aggressive, I don't get the extra five-year protection from hormone therapy. If women taking this drug can have recurrences after completing the therapy, I wonder what's in store for me having not had it.

Maybe I'm making comparisons that don't amount to any real conclusions. Perhaps my type of disease allows for a more secure future. Or perhaps it places me on shaky ground. I don't know for sure. And I don't think I'll dive any deeper into research than I already have. Instead, I will live for today -- while enjoying the announcement my oncologist shared with me yesterday. All clear!

There are sometimes silver linings to the darkest of cancer clouds. I know -- because I have the dark cloud of HER2 positive breast cancer hanging over my head. HER2 positive means the tumor removed from my breast was aggressive. It aggressively over-expressed a protein that accelerates tumor growth. And it led to a poor prognosis -- that might be considered a good one too.

You see, research on the whole HER2 issue is turning up some pretty powerful potions. Like Herceptin -- the drug that miraculously cuts recurrence upwards of 50 percent for positive women like me. I was a lucky recipient of this drug. And the pharmacist who mixed the drug for all 17 of my infusions tells me it's really a good thing I have this HER2 problem -- because the drugs created to attack the problem may just cure me of my disease.

So in an odd turnabout -- from bad luck to good fortune -- I am not so sad my tumor was aggressive. It means there are bonus treatments for me. And if my cancer comes back and Herceptin no longer works, there is another drug called Tykerb. And now the Army is leading its own breast cancer vaccination study. The focus -- HER2.

Early study results from Walter Reed Army Medical Center in Washington, D.C. suggest a 50 percent reduction in disease recurrence for HER2 positive women who receive a vaccination of AE37.

AE37 targets HER2 and boosts the body's immune system so it can battle the protein before it stimulates growth. It's similar to Herceptin, but the activity of AE37 stimulates a patient's own immune system to recognize the cancer target rather than interacting with the target directly.

Should the Food and Drug Administration decide to support this study, it will proceed to Phase 3 testing, which includes a much larger pool of participants.

Last week, I watched actress Emma Thompson portray with real power a life derailed by cancer in the 2001 HBO screen adaptation of the Pulitzer Prize-winning drama Wit by Margaret Edson.

I watched the movie, on DVD and in the privacy of my own home, almost six years after it was released -- and two years after my own cancer derailment. I like the order in which it all happened -- having cancer and then watching the movie, rather than watching the movie and then having cancer.

Thompson's portrayal of Vivian Bearing, Ph.D., professor of 17th-century English poetry, and expert on the sonnets of John Donne, was entirely real -- so real I sometimes felt I was reliving my own journey with cancer.

The cold, impersonal delivery of Bearing's treatment plan -- eight high-dose, experimental chemotherapy treatments taken over the course of eight months for stage-four metastatic ovarian cancer, an aggressive and advanced form -- reminded me of the matter-of-fact manner in which doctors speak to patients, the manner in which my own oncologist spoke to me, void of compassion and warmth and concern.

The on-going sterile and clinical interactions Bearing encounters from doctors, technicians, nurses, and medical students allowed me to appreciate the very few caring souls who crossed my medical path.

Bearing resolves to become a scholar on cancer, just as she has on Donne. And while I am no Ph.D. scholar, I did study cancer, sometimes to a fault, in order to acquire some sort of control over what was happening to me.

Chemotherapy makes Bearing sick. It made me sick too. Chemotherapy lands Bearing in hospital isolation. It landed me there too. Cancer scares Bearing. It scared me too.

Sometimes, cancer -- the return of cancer -- still scares me. But mostly, I am happy to be alive, happy to be watching movies that authentically capture the reality of cancer, movies that make me proud to have overcome what Bearing's doctor calls an insidious disease.